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Abstract
Human dengue virus infection without mosquito vector has been reported to occur as a result of mucocutaneous
transmission, needlestick in patient care and laboratory accident, blood transfusion, bone marrow transplant, organ
transplant, intrapartum and perinatal transmission, and breastfeeding. The emergence of Zika virus, another
mosquito-borne flavivirus, has illustrated additional potential routes of non-vector transmission in humans. A
recent study in another flavivirus, Japanese encephalitis virus, in pigs has also demonstrated non-vector transmission.
We highlight some reports on dengue virus that have documented non-vector transmission and that are relevant to
the transmission of Zika virus and other flaviviruses.
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Background
Dengue virus (DENV) is a flavivirus transmitted via the
bite of the female Aedes mosquitoes, usually Aedes
aegypti and Aedes albopictus. Rare cases of non-vector
DENV transmission have been reported in the literature
involving many routes including mucocutaneous expos-
ure, needlestick in patient care and laboratory accident,
blood transfusion, bone marrow transplant, organ trans-
plant, intrapartum and perinatal transmission, and
breastfeeding [1–3]. Until the Zika virus (ZIKV) out-
breaks in the Americas led to the recognition of non-
mosquito-borne transmission, most reports on flavivirus
transmission via non-vector routes have been on DENV,
with rare reports on other flaviviruses. We highlight
some published reports and re-examine the potential of
DENV transmission without a mosquito vector.
Main text
Non-vector transmission in DENV
Among the flaviviruses, DENV and yellow fever (YF) are
known to cause hemorrhagic manifestations. Because of
the higher incidence and much broader distribution of
DENV, and its associated thrombocytopenia and
hemorrhagic manifestations, DENV potentially has the
greatest associated risk for direct or nosocomial trans-
mission. Human DENV infection without mosquito vec-
tor has been documented primarily in case reports
(Table 1). Several cases of DENV transmission via muco-
cutaneous or needlestick exposure were identified in
non-endemic countries, all in patient care and laboratory
settings [1, 4–8]. Of note, one case occurred in a health-
care worker that sustained a blood splash to face from a
patient with confirmed DENV infection [1]. Because of
the proximity of blood near mucous membranes and
lack of percutaneous exposure, this case was considered
to be a result of mucocutaneous transmission, while oro-
nasal or aerosol transmission could not be proven.
DENV transmission has also occurred via blood trans-
fusion [9–11], bone marrow transplant [12], and solid
organ transplant [13]. Despite the concern for transmis-
sion risk from patients with bleeding diathesis, these re-
ported cases of DENV infection from non-vector
transmission were not attributed to sources with
hemorrhagic manifestations.
The effect of vertical transmission of DENV on infants
is highly relevant given the concern resulting from the
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recognition of ZIKV to cause adverse fetal outcomes in-
cluding microcephaly. Many cases of intrapartum and
perinatal DENV transmission have been described but
none have reported congenital abnormalities [14–17].
Systematic reviews to date have found an association of
dengue infection during pregnancy with increased rates
of preterm birth and low birth weight [18, 19]. One
meta-analysis that included 6071 pregnant women, of
whom 292 had DENV infection during pregnancy, found
an odds ratio of 1 · 71 (95 % CI 1 · 06–2 · 76) for preterm
birth and an odds ratio of 1 · 41 (95 % CI 0 · 90–2 · 21)
for low birth weight in those with DENV infection. The
study also identified an association with miscarriage (OR
3.51:95 % CI 1.15–10.77) [19].
Because vertical transmission of DENV usually oc-
curred in endemic countries, confirmation faced chal-
lenges in areas where testing may not be readily
available. For example, a case series from Sri Lanka
of women with DENV infection during pregnancy did
not document infection in most of the newborns [20].
In contrast, other cases of infants born to mothers
with confirmed DENV infection just before delivery
have illustrated intrapartum or perinatal transmission;
the newborns typically developed febrile illnesses with
thrombocytopenia [16, 18, 21–26]. Some series in-
cluded women with hemorrhagic manifestations in
the peripartum period [16, 21–23, 25]. They delivered
infants who developed febrile illness confirmed to be
DENV, but most infants recovered. Nevertheless, fa-
tality has been reported in infants born to mothers
with severe DENV infection [15], as well as maternal
and fetal death, and miscarriage [20]. Thus, outcomes
of vertical transmission of DENV in neonates ranged
widely.
Most previous cases of intrapartum and perinatal
transmission were presumed to be via placental transfer
of virus. In 2012, a case in New Caledonia of vertical
transmission occurred possibly via breastfeeding [3]. The
mother had fever, anemia, and thrombocytopenia peri-
partum (2 days before delivery) that was later confirmed
to be DENV infection [3]. The infant also developed
fever and thrombocytopenia but recovered. Serial blood
samples of the mother and infant and breast milk were
positive for DENV by RT-PCR, but not the cord blood
[3]. Viral loads in breast milk and mother’s blood on the
same day were similar, and virus was cultured from
breast milk, thus confirming the passage of DENV via
breast milk [3]. This case report called attention to the
potential role of breastfeeding in transmitting DENV, a
possible mechanism in perinatal infections.
Lastly, some investigators have proposed the possibil-
ity of DENV transmission via aerosol route. This mech-
anism was suggested in 21 healthcare workers who
were serologically confirmed to have nosocomial DENV
and where there was no known needlestick or mucocu-
taneous exposure to DENV-infected blood [27]. To
date, aerosol transmission of DENV in humans lacks
confirmation.
Non-vector transmission of ZIKV
The rapid spread of ZIKV infection has brought aware-
ness about its transmission via non-vector routes and
suggest areas of study needed for DENV. The most im-
portant non-vector route appears to be sexual contact.
Table 1 Summary of published cases of DENV transmission via non-vector routes
Route of transmission Comment References
Mucocutaneous A health care worker who was splashed in the face by blood from a confirmed dengue patient was




Health care workers including laboratory personnel acquired DENV infection after needlestick injuries. 4–8
Blood transfusion Transfusion-transmitted dengue has been documented in Brazil and American Red Cross/CDC Dengue
Branch; a DENV-4 outbreak in Brazil resulted in transfusion transmission in about a third of recipients of
RNA-positive donations.
9–11
Bone marrow transplant Transmission of DENV-4 in a 6-year old child from Puerto Rico via bone marrow transplant led to a fatality. 12
Solid organ transplant DENV transmission occurred from donor to recipient after living donor liver transplantation. 13
Intrapartum/perinatal Newborns whose mothers had acute DENV infections in the peripartum period developed dengue
infection, ranging from mild febrile illness with thrombocytopenia to severe manifestations.
14–26
Case reports have documented intracerebral hemorrhage and fatality in infants.
Systematic reviews and meta-analysis found increase risk for miscarriage for women with dengue during
pregnancy, preterm birth, and low birthweight.
18–19
Breast milk A woman confirmed to have DENV infection postpartum breastfed on days 2–4 of her illness. The infant
developed symptoms of dengue starting on day 4 of mother’s illness, was confirmed by PCR with high
viral load in blood, and breast milk was positive by PCR and culture.
3
Oronasal No confirmed transmission reported, but the case of mucocutaneous exposure raises possibility of oronasal infection. 1
Sexual None reported -
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Such transmission associated with returning travelers
has been documented in several countries [28–32]. In
2008, a case of probable male-to-female sexual transmis-
sion occurred in a Colorado couple where a male scien-
tist returning from Senegal and his wife who did not
travel both were confirmed to have ZIKV [33]. Another
was an autochthonous case in Florence, Italy, 2014,
where sexual transmission occurred between a man who
returned from Thailand and his girlfriend who had not
traveled [32]. More recently, male-to-male sexual trans-
mission of ZIKV was confirmed in Texas between a
traveler returning from Venezuela and his partner who
had not traveled [29]. Additional cases in several coun-
tries that lack autochthonous ZIKV circulation are under
investigation. [28] Importantly, semen from a Tahitian
man with hematospermia tested positive for ZIKV and
the virus was replicative [34]. Another report suggested
the possibility of long ZIKV persistence in semen in a
68-year-old man who was diagnosed with ZIKV infec-
tion in 2014 after returning to the UK from Cook
Islands; his convalescent phase semen was positive for
ZIKV by real-time reverse transcription PCR at 27 and
62 days after symptoms onset [35]. Belgian investigators
that followed 4 ZIKV-infected men have also reported
persistence of ZIKV RNA in semen up to days 56 and
68 in two of the men [36]. Such information will con-
tribute to the basis of recommendations for ZIKV
prevention.
A notable report raised the possibility of transmission
through oral (saliva) or other body fluids besides semen
in a woman living in Paris who had not traveled to any
area with ZIKV circulation. She had sexual contact, both
vaginal and oral, several times with a man who had been
in Brazil and who had symptoms of ZIKV that resolved
a day before their first contact [30]. In the woman, urine
and saliva were positive for ZIKV RNA; her serum PCR
was negative for ZIKV RNA but IgM was positive; vagi-
nal swab was negative for ZIKV RNA. The index patient
had positive urine for ZIKV RNA but plasma and saliva
were negative; his semen culture grew ZIKV on days 18
and 24 [30]. Although ZIKV has previously been identi-
fied in saliva, [37, 38] including cultivable virus [38],
transmission via saliva has not been documented to date.
A case of ZIKV infection following a monkey bite in
Indonesia and diagnosed in Australia suggested that
transmission may have occurred through saliva, but
mosquito transmission could not be ruled out [39].
Other studies have also reported positive tests for
ZIKV in saliva and urine with ZIKV typically persisting
longer in semen, saliva, and urine than in blood [34, 38,
40]. Although transmission has not been definitively de-
scribed as a result of saliva or urine, it is conceivable that
infection can occur from exposure to any body fluids
that have replicative ZIKV. Percutaneous exposure has
resulted in ZIKV infection. Cases in laboratory setting
have been documented as well as subcutaneous injection
of ZIKV-containing suspension to a volunteer [41, 42].
Recently, a study on a woman infected with Zika virus
has demonstrated the presence of ZIKV RNA in endo-
cervical swab, cervical mucus, and genital swab [43].
The clinical relevance manifested in a separate case re-
port of female to male transmission [44].
Persons infected with ZIKV but who are asymptomatic
are potential sources for transfusion transmission of the
virus. During the French Polynesia ZIKV outbreak,
nearly 3 % of blood donations tested positive for ZIKV
by PCR. Perinatal transmission of ZIKV has been identi-
fied [45]. Many studies now support the causality link
between infection during pregnancy and subsequent
congenital microcephaly and other developmental ab-
normalities [46–48]. Breast milk has also tested positive
for ZIKV by PCR, although culture did not yield repli-
cative ZIKV; transmission via breast milk has not been
shown to date [45, 49].
Non-vector transmission of other flaviviruses
Other flaviviruses related to DENV and ZIKV include
Japanese encephalitis virus (JEV), Murray Valley enceph-
alitis, St. Louis encephalitis, West Nile virus (WNV),
and yellow fever (YF). Transmission of these viruses oc-
curs nearly always via mosquito bites, although rare hu-
man cases of non-vector transmission have occurred for
JEV, WNV, and YF [50]. Studies in animals have also
established viral spread via oral, intragastric, intranasal/
aerosol, percutaneous, cutaneous, and mucous mem-
brane exposure [50].
A recent article described vector-free transmission
and persistence of JEV in pigs [51]. JEV is known to
have a cycle involving waterbirds and Culex mosquitoes
and a cycle involving pigs as amplifying hosts. However,
investigation of some JE outbreaks failed to detect virus
in local mosquitoes [51], which raised the question of
alternative routes of transmission. By placing sentinel
pigs with intravenously infected pigs, the investigators
found that intravenously-infected animals developed
fever after 24 h that lasted for 4–5 days; viremia per-
sisted 3 days. Sentinel pigs in contact with infected pigs
demonstrated viremia for 2–4 days. Examination of or-
gans of injection-infected pigs found positive viral RNA
in the lymph nodes, the ileum, parts of the nasal cavity,
the brain, with particularly high levels in the tonsils.
Shedding of virus occurred as early as 2 days after nee-
dle infection; cell cultures were positive confirming
presence of live virus in oronasal swabs. Animals in-
fected by contact shed live virus 6–10 days after con-
tact; most oronasal swabs became positive for viral
RNA about 4–7 days after infection; virus was isolated
from most swabs. Histopathological CNS lesions were
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demonstrated for both needle-infected and contact-
infected pigs. Interestingly, viral RNA was still present
in the tonsils at 25 days post injection after infection
but not other organs.
In summary, pigs shed JEV in oronasal secretions
and can be infected via the oronasal route. Whether
infected by injection, close contact, or oronasal inocu-
lation, clinical symptoms, virus tropism, and CNS
histological lesions were similar. The tonsils were
prominent sites of virus replication and JEV persisted
there for ≥25 days despite high levels of neutralizing
antibodies.
Challenges in determining non-vector routes of transmission
of DENV
Studies in animals on the transfer of DENV via aerosol
or intranasal or oral route have not been done. One
challenge has been the lack of adequate animal models
for DENV. Non-human primates can be infected with
DENV but do not become symptomatic [52]. A recently
developed mouse model (AG129 mice) has contributed
to some understanding of human infection with DENV
[52], but there are no reports to date of AG129 mice de-
veloping DENV infection via direct contact or oronasal
exposure with infected mice.
Clearly non-vector transmission of DENV has oc-
curred, and many possible routes have been described.
The overall burden of DENV infection from known
non-vector transmission appears to be low. Primarily
the non-vector routes involve percutaneous or mucocu-
taneous exposure to infectious blood, vertical transmis-
sion, and receipt of infected products for treatment.
Many of these have also been reported with ZIKV in
current outbreaks, and some have also been described
with other flaviviruses such as WNV and YFV [50]. For
instance, vaccine strain of YFV has been transmitted
via breastmilk resulting in febrile illness and meningo-
encephalitis in the infants [53–55]. Good infection con-
trol is the key to controlling DENV via non-vector
transmission.
Unlike the ZIKV reports that document sexual trans-
mission and the JEV study in pigs that confirmed
oronasal transmission, DENV infection has not been at-
tributed specifically to these routes of transmission.
One case report of the blood splash to face that led to
confirmed DENV infection was considered mucocuta-
neous transmission, but oronasal transmission might
have been plausible. Possibly, oronasal and sexual
routes of exposure can lead to DENV transmission, but
are difficult to distinguish from mosquito-borne trans-
mission in endemic countries where mosquito vectors
are widely present.
It is also possible that routes of non-vector transmis-
sion of flaviviruses differ from each other. For DENV
and ZIKV, infections in pregnant women clearly lead to
different birth outcomes. While DENV in pregnant
women has been associated with low birth weight in-
fants and preterm birth, no congenital abnormality has
been found, but detailed prospective studies are lacking.
On the other hand, ZIKV acquired in utero has the
much more severe consequence of microcephaly and
multiple other abnormalities.
Current knowledge gaps with respect to DENV non-vector
transmission and public health implications of possible
route of transmission
Many knowledge gaps in DENV non-vector transmission
remain. Key questions that need exploration in view of
discoveries from ZIKV include:
 Are there additional routes of DENV transmission,
including oral, intragastric, intranasal/aerosol, and
sexual routes?
 Is DENV present in body fluids other than blood
and breast milk (urine, semen, vaginal secretions,
saliva, tears), and what are the virus kinetics in these
body fluids?
 If DENV is present in other body fluids, how long
does it persist?
 What is the potential of DENV transmission via
sexual contact?
 Is there any possible association of vertical
transmission of DENV with congenital
abnormalities?
 Is it possible for DENV transmission via
breastfeeding to cause significant harm in infants?
 In dengue-endemic countries where mosquitos are
ubiquitous, how will it be possible to determine
whether a case of DENV is acquired via a mosquito
bite or a non-mosquito route?
Conclusion
In conclusion, documenting and confirming non-vector
routes of transmission of DENV faces challenges. Aedes
mosquitoes, the vectors of disease, are ubiquitous in
most countries endemic for DENV and bites occur
despite preventive measures; therefore vector-borne
transmission is implicated foremost as the exposure.
Non-vector transmission is more likely to be suspected
in non-endemic countries that detect unusual infec-
tions with some link to returning traveler or unusual
exposures. Studies on DENV transmission in animal
models, like the study on JEV in pigs, would be helpful
in our understanding of non-vector transmission of
DENV. Similar studies will also be relevant in gaining
deeper understanding of the pathogenesis and trans-
mission of ZIKV.
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